$-0.23 EPS Expected for BioDelivery Sciences International, Inc. (BDSI)

February 18, 2018 - By Linda Rogers

 $ 0.23 EPS Expected for BioDelivery Sciences International, Inc. (BDSI)
Investors sentiment increased to 1.67 in Q3 2017. Its up 0.67, from 1 in 2017Q2. It improved, as 8 investors sold BioDelivery Sciences International, Inc. shares while 7 reduced holdings. 6 funds opened positions while 19 raised stakes. 20.34 million shares or 6.83% more from 19.04 million shares in 2017Q2 were reported.
Renaissance Tech Ltd Com, New York-based fund reported 585,200 shares. Broadfin Cap Llc reported 1.92% of its portfolio in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). Comml Bank Of New York Mellon reported 44,280 shares. Hikari Pwr stated it has 0.23% of its portfolio in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). Price T Rowe Associate Md has invested 0% of its portfolio in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). 37,715 were reported by Valley National Advisers. Salem Inv Counselors reported 17,200 shares or 0.01% of all its holdings. California Public Employees Retirement System owns 259,400 shares or 0% of their US portfolio. Barclays Pcl has invested 0% in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). Grandeur Peak Global Advisors Ltd owns 0.51% invested in BioDelivery Sciences International, Inc. (NASDAQ:BDSI) for 1.14 million shares. Bancorp Of Montreal Can, Ontario – Canada-based fund reported 968,936 shares. Jacobs Levy Equity Mngmt owns 219,869 shares. The North Carolina-based Financial Bank Of America De has invested 0% in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). Grp One Trading Lp owns 2,925 shares. Fny Managed Accounts Lc has invested 0.01% in BioDelivery Sciences International, Inc. (NASDAQ:BDSI).

Since September 14, 2017, it had 0 insider purchases, and 2 insider sales for $2.51 million activity.

Analysts expect BioDelivery Sciences International, Inc. (NASDAQ:BDSI) to report $-0.23 EPS on March, 16.They anticipate $0.06 EPS change or 20.69 % from last quarter’s $-0.29 EPS. After having $-0.21 EPS previously, BioDelivery Sciences International, Inc.’s analysts see 9.52 % EPS growth. It closed at $2.1 lastly. It is down 24.37% since February 18, 2017 and is uptrending. It has outperformed by 7.67% the S&P500.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Ratings Coverage

Among 7 analysts covering BioDelivery Sciences International (NASDAQ:BDSI), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioDelivery Sciences International had 32 analyst reports since August 16, 2015 according to SRatingsIntel. Roth Capital maintained BioDelivery Sciences International, Inc. (NASDAQ:BDSI) on Monday, November 13 with “Buy” rating. The stock has “Buy” rating by Cantor Fitzgerald on Thursday, November 9. Cantor Fitzgerald downgraded the shares of BDSI in report on Wednesday, May 11 to “Hold” rating. The firm earned “Buy” rating on Friday, May 26 by H.C. Wainwright. The company was maintained on Friday, June 23 by H.C. Wainwright. The firm earned “Mkt Perform” rating on Tuesday, November 10 by FBR Capital. Piper Jaffray maintained the stock with “Buy” rating in Wednesday, August 9 report. The rating was maintained by Roth Capital on Friday, March 11 with “Buy”. Cantor Fitzgerald upgraded BioDelivery Sciences International, Inc. (NASDAQ:BDSI) on Wednesday, May 17 to “Overweight” rating. The stock has “Buy” rating by Cantor Fitzgerald on Wednesday, August 23.

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company has market cap of $117.36 million. The firm provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, which consists of a small, erodible polymer film for application to the buccal mucosa. It has a 20.79 P/E ratio. It offers ONSOLIS, a fentanyl buccal soluble film to treat breakthrough pain in opioid patients with cancer; BUNAVAIL, a buprenorphine and naloxone buccal film for the treatment of opioid dependence; and BELBUCA, a buprenorphine buccal film for the treatment of chronic pain.

More notable recent BioDelivery Sciences International, Inc. (NASDAQ:BDSI) news were published by: Seekingalpha.com which released: “BioDelivery Sciences: Change Is Good?” on September 29, 2017, also Prnewswire.com with their article: “BioDelivery Sciences Announces Patent Litigation Settlement Agreement with Teva” published on October 12, 2017, Seekingalpha.com published: “BioDelivery Sciences: Belbuca’s Progress Is Encouraging” on June 02, 2017. More interesting news about BioDelivery Sciences International, Inc. (NASDAQ:BDSI) were released by: Globenewswire.com and their article: “BioDelivery Sciences Announces BELBUCA® Patent Litigation Settlement Agreement …” published on February 06, 2018 as well as Prnewswire.com‘s news article titled: “BioDelivery Sciences to Present at the 29th Annual Piper Jaffray Conference” with publication date: November 16, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: